Jubilant Life shares fall on US FDA warning letter
REUTERS - Shares in Jubilant Life Sciences Ltd (JULS.NS) fell as much as 6.9 percent on Wednesday after U.S. health regulators issued a warning letter to the company, citing "significant violations" of manufacturing standards at its facility in Canada.
The U.S. Food and Drug Administration may hold drug approvals until Jubilant HollisterStier General Partnership takes necessary corrective steps, Jubilant said in a statement.
Other bigger Indian companies such as Dr. Reddy's Laboratories Ltd (REDY.NS), Ranbaxy Laboratories Ltd (RANB.NS), Sun Pharmaceutical Industries Ltd (SUN.NS) and Aurobindo Pharma (ARBN.NS) have all received regulatory warning letters on compliance over the last four years.
The company said its on-going manufacturing, distribution and sale of products would not be affected by the warning letter, and it plans to respond to the drug regulator on or before March 15.
Shares in Jubilant Life Sciences, which has a market value of about $548.5 million, fell 4.25 percent to 178 rupees. They earlier touched a low of 173 rupees. The Sensex was up 0.67 percent.
(Reporting by Kaustubh Kulkarni in Mumbai; Editing by Anand Basu)
- Tweet this
- Share this
- Digg this
- Iran prosecutor gives government 30 days to block social media
- Islamic State closes in on Syrian town, refugees flood into Turkey
- Nationalist leader says Scots tricked out of independence
- Study asks whether artificial sweeteners may drive diabetes
- CORRECTED-UPDATE 3-Tens of thousands crowd New York streets for climate march
GROUP OF 20
The G20 leading nations say they are tantalisingly close to adding an extra $2 trillion to the global economy and creating millions of new jobs, but Europe's extended stagnation remains a major stumbling block. Full Article
Top rice exporter India importing over 100,000 T on temporary supply squeeze. Full Article